🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Omission of Axillary Lymph Node Dissection in Case of Tumor Spread to Lymph Nodes in the Armpit in Breast Cancer

RecruitingNAAges 18 Years - anyAllKarolinska Institutet
NCT06869629 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

SENOMAC-ULTRA enrols patients who are planned for upfront surgery for a breast cancer that has spread to lymph nodes in the armpit, and that have been detected already prior to surgery by imaging, e.g. ultrasonography. In this situation, a full axillary lymph node dissection, removing more than 10 lymph nodes from the arm pit, is unnecessarily extensive in about half of the patients. More extensive surgery leads to a risk for arm lymphedema and functional problems with the arm and shoulder region, which should be avoided if not beneficial for diagnosis or prognosis. This trial seeks to ascertain that less extensive surgery, performed by only removing the first lymph node/s in the armpit (the sentinel lymph node/s) and the known metastatic lymph nodes (targeted axillary dissection, TAD), offers non-inferior survival outcomes to a full axillary lymph node dissection.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients with primary invasive breast cancer clinical stage II-III * Palpable or non-palpable axillary metastases visible by ultrasound (other imaging accepted if confirmatory ultrasound is performed) and confirmed by fine needle aspiration or core biopsy * Written informed consent * Age ≥ 18 years Exclusion Criteria: * Distant metastases * Ipsilateral metastases in internal mammary, infra- or supraclavicular lymph nodes without confirmed axillary nodal involvement * Preoperative suspicion of extensive nodal involvement, i.e. locally advanced disease * Nodes fixed to each other or to neighbouring structures on palpation or imaging * History of contralateral invasive breast cancer within 5 years * Bilateral invasive breast cancer if (i) one side meets any exclusion criteria or (ii) both sides meet all inclusion criteria * Pregnancy * Neoadjuvant systemic treatment (short course of neoadjuvant endocrine therapy \<three months is allowed) * Medical contraindications for or expressed preoperative wish to abstain from radiotherapy or the recommended adjuvant systemic treatment which complies with standard of care, taking age and comorbidity into consideration * Inability to absorb or understand the meaning of the study information; for example, through disability, inadequate language skills or dementia
💊

What it tests

  • Targeted axillary dissection
  • Axillary lymph node dissection
📍

Where

4 sites
Helsinki University Hospital
Helsinki, Finland
Samsung Medical Center
Seoul, South Korea
Skåne University Hospital
Malmö, Sweden
Örebro University Hospital
Örebro, Sweden
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy